Atorvastatin lowers plasma low-density lipoprotein cholesterol and C-reactive protein in Japanese type 2 diabetic patients

Metabolism: Clinical and Experimental

Volumn 55, Issue 1, 2006, Pages 67-71

  Yamada, Satoru ^a   Yanagawa, Tatsuo ^b   Sasamoto, Kazuo ^c   Araki, Atsushi ^d   Miyao, Mariko ^e   Yamanouchi, Toshikazu ^f  

^a KITASATO INSTITUTE HOSPITAL   (Japan)

^b Nerima General Hospital   (Japan)

^c Itabashi Chuo Medical Center   (Japan)

^d Tokyo Metropolitan Institute of Gerontology   (Japan)

^e The Mutualaid Association of Public School Teachers)   (Japan)

^f TEIKYO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ATORVASTATIN; C REACTIVE PROTEIN; CHOLESTEROL; CREATININE; HEMOGLOBIN A1C; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; AGED; ARTICLE; BLOOD CHEMISTRY; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; JAPAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN DETERMINATION; URINALYSIS;

ADULT; BIOLOGICAL MARKERS; BLOOD PRESSURE; C-REACTIVE PROTEIN; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; ENDOTHELIUM, VASCULAR; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION MEDIATORS; JAPAN; LIVER; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PYRROLES;

EID: 28444451901     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2005.07.017     Document Type: Article

References (36)

1. M. Kubo, Y. Kiyohara, and I. Kato Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community: the Hisayama study Stroke 34 2003 2349 2354
2. T. Nakagami, R. Kawahara, and M. Miyamae The cause of death in Japanese non-insulin-dependent diabetes mellitus patients J Jpn Diab Soc 41 1998 897 906
3. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
4. The Scandinavian Simvastatin Survival Study Group Randomized trial of cholesterol lowing in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383 1389
5. J. Shepherd, S.M. Cobbe, and I. Ford Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group N Engl J Med 333 1995 1301 1307
6. F.M. Sacks, M.A. Pfeffer, and L.A. Moye The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators N Engl J Med 335 1996 1001 1009
7. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels N Engl J Med 339 1998 1349 1357
8. J.R. Downs, M. Clearfield, and S. Weis Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study JAMA 279 1998 1615 1622
9. I. Jialal, D. Stein, and D. Balis Effect of hydroxy methylglutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels Circulation 103 2001 1933 1935
10. P.M. Ridker, N. Rifai, and M. Clearfield Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events N Engl J Med 344 2001 1959 1965
11. P.M. Ridker, N. Rifai, and S.P. Lowenthal Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia Circulation 103 2001 1191 1193
12. M.A. Albert, E. Danielson, and N. Rifai Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study JAMA 286 2001 64 70
13. P.M. Ridker, M. Cushman, and M.J. Stampfer Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men N Engl J Med 336 1997 973 979
14. P.M. Ridker, C.H. Hennekens, and J.E. Buring C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women N Engl J Med 342 2000 836 843
15. P.M. Ridker, N. Rifai, and L. Rose Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events N Engl J Med 347 2002 1557 1565
16. J. Danesh, J.G. Wheeler, and G.M. Hirschfield C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease N Engl J Med 350 2004 1387 1397
17. P.A. Economides, A. Caselli, and E. Tiani The effects of atorvastatin on endothelial function in diabetic patients and subjects at risk for type 2 diabetes J Clin Endocrinol Metab 89 2004 740 747
18. Antithrombotic Trialists' Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 324 2002 71 86
19. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT) JAMA 288 2002 2998 3007
20. P.S. Sever, B. Dahlof, N.R. Poulter ASCOT investigators Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial Lancet 361 2003 1149 1158
21. H.M. Colhoun, D.J. Betteridge, P.N. Durrington CARDS investigators Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial Lancet 364 2004 685 696
22. American Diabetes Association Dyslipidemia management in adults with diabetes Diabetes Care 27 2004 S68 S71
23. Japan Atherosclerosis Society Japan Atherosclerosis Society (JAS) guidelines for diagnosis and treatment of atherosclerotic cardiovascular diseases 2002 Japan Atherosclerosis Society Tokyo 12
24. A.V. Chobanian, G.L. Bakris, H.R. Black the National High Blood Pressure Education Program Coordinating Committee The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure JAMA 289 2003 2560 2572
25. European Society of Hypertension-European Society of Cardiology Guidelines Committee 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension J Hypertens 21 2003 1011 1053
26. H. Seino, H. Yamaguchi, and M. Kimura Evaluation of effect of HMG-CoA reductase inhibitors on the hypercholesterolemia associated with diabetes Prog Med 23 2003 727 735
27. K. Sasamoto A study of the efficacy and safety of long-term atorvastatin treatment in type 2 diabetic patients with hypercholesterolemia Prog Med 23 2003 2381 2388
28. S. Nakanishi, K. Yamane, and N. Kamei Elevated C-reactive protein is risk factor for the development of type 2 diabetes in Japanese Americans Diabetes Care 26 2003 2754 2757
29. Y. Saijo, N. Kiyota, and Y. Kawasaki Relationship between C-reactive protein and visceral adipose tissue in healthy Japanese subjects Diabetes Obes Metab 6 2004 249 258
30. R. Kawate, M. Yamakido, and Y. Nishimoto Diabetes mellitus and its vascular complications in Japanese migrants on the island of Hawaii Diabetes Care 2 1979 161 170
31. S.M. Kent, and A.J. Taylor Usefulness of lowering low-density lipoprotein cholesterol to <70 mg/dL and usefulness of C-reactive protein in patient selection Am J Cardiol 92 2003 1224 1227
32. Y. Kiyohara Joint Committee of Japan Atherosclerosis Society and Japan Diabetes Society Prevalence of cardiovascular disease and association among its risk factor in the Japanese type 2 diabetic patients: the Hisayama study Diabet Complicat 14 2000 80 84 [in Japanese]
33. M. Matsuzaki, T. Kita, H. Mabuchi J-LIT Study Group Japan Lipid Intervention Trial. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia Circ J 66 2002 1087 1095
34. H. Mabuchi, T. Kita, M. Matsuzaki J-LIT Study Group Japan Lipid Intervention Trial. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia and coronary heart disease: secondary prevention cohort study of the Japan Lipid Intervention Trial (J-LIT) Circ J 66 2002 1096 1100
35. H. Sone, S. Mizuno, Y. Ohashi Japan Diabetes Complications Study Group Prevention and therapeutic strategy of metabolic syndrome-implications from the interim results of Japan Diabetes Complications Study (JDCS) Nippon Rinsho 62 2004 1150 1157
36. S.M. Haffner, S. Lehto, and T. Ronnemaa Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction N Engl J Med 339 1998 229 234